1.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SUGEN-SU5416.031, CDR0000067499, UCLA-9909008, NCT00004252
|
|
2.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-001003701, SUGEN-SU5416.035, NCI-G01-1980, NCT00021281
|
|
3.
|
Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-9901075, SUGEN-SU5416.010, NCI-G99-1546
|
|
4.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NABTC-9902, MSKCC-01045, NCI-00-C-0173, NABTC-99-02, NCT00004868
|
|
5.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MDA-ID-99341, NCI-673, NCT00005942, 673
|
|
6.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MDA-ID-99243, NCI-88, NCT00005818, 88
|
|
7.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-S-0120, NCT00023725
|
|
8.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-S-0121, NCT00023738
|
|
9.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067633, AMC-022, NCT00005042
|
|
10.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: DFCI-00002, NCI-330, NCT00005862, 330
|
|
11.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-NCI-52, 10411, NCI-52, NCT00006001, 52
|
|
12.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068010, UCCRC-10428, UCCRC-NCI-49, NCI-49, 49, NCT00006002
|
|
13.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-10395, NCI-48, NCT00006003, 48
|
|
14.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: FCCC-00009, NCI-58, NCT00006013, 58
|
|
15.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-10409, UCCRC-NCI-44, NCI-44, NCT00006014, 44
|
|
16.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-00049, NCI-79, NCT00006361, 79
|
|
17.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 00041, U01CA062505, P30CA033572, CHNMC-PHII-23, NCI-T99-0085, CDR0000068262, T99-0085, NCT00006384
|
|
18.
|
Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: MDA-ID-99291, NCI-1290, NCT00009919, 1290
|
|
19.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UTHSC-IDD-99-27, SACI-IDD-99-27, NCI-66, NCT00017316, 66
|
|
20.
|
Phase: Phase II Type: Treatment Status: Completed Age: Not specified Sponsor: NCI Protocol IDs: GOG-0227B, NCT00026260
|
|
21.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SUGEN-SU5416.003, CDR0000066829, LAC-USC-17K981, NCT00003720
|
|
22.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CWRU2Y99, U01CA062502, P30CA043703, NCI-T99-0095, T99-0095, NCT00005642
|
|
23.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CWRU5199, U01CA062502, P30CA043703, NCI-T99-0099, T99-0099, NCT00005822
|
|
24.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CWRU1399, U01CA062502, P30CA043703, NCI-T99-0084, T99-0084, NCT00005647
|
|
25.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0002046, SUGEN-ND019901/SE5416.102, NCI-G00-1805, NCT00005996
|